Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

NCT02243007 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02243007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02243007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2014
Completion date
June 30, 2016
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal carcinoma, resectable pancreatic cancer